Drug Approval | January 08, 2026
Rapid-acting ADHD treatment Azstarys now approved in China
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Heart failure affects an estimated 64.3 million people worldwide
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
India’s pharmaceutical sector stands at a pivotal inflection point
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Subscribe To Our Newsletter & Stay Updated
